Introduction
Peroxisome proliferator-activated receptors (PPARs) are members of a nuclear hormone receptor superfamily of ligand-activated transcriptional factors that also includes thyroid, steroid and retinoid receptors. Out of the three subtypes known (PPARα, PPARβ/δ and PPARγ), PPARγ has been the most extensively investigated. PPARγ is known to be critically involved in the regulation of glucose and lipid metabolism, but more recent results also revealed an important role of PPARγ in the regulation immune response [6] , gathering an increasing research interest in the field of disorders involving autoimmune processes in the pathomechanism, such as multiple sclerosis (MS) [11, 27] .
MS is a chronic debilitating inflammatory central nervous system (CNS) disorder, characterized by demyelination, axonal and neuronal degeneration. The disease is supposed to be of autoimmune origin, in which encephalitogenic T-helper 1 (Th1) and interleukin 17 (IL-17)-producing Th17 lymphocytes are proposed to be the main mediators [1] . In the past years, natural and synthetic agonists of PPARγ were shown to effectively ameliorate the course of experimental autoimmune encephalitis (EAE), a widely used experimental model of MS, by inhibiting the expansion of encephalitogenic T cells [8, 9, 13, 21, 23, 29, 35] . More recently, the activation of PPARγ in both human and murine CD4+ T cells have been shown to potently inhibit the differentiation towards the Th17 lineage [16] , and the eicozapentaenoic acid-induced amelioration of EAE has been reported to be accompanied by increased PPARγ in association with decreased IL-17 expression in CNS-infiltrating CD4+ T cells [35] .
Conversely, pharmacological inhibition of [28, 29] or a heterozygous deficiency in PPARγ [22, 28, 29] leads to an exacerbated course of EAE in mice in association with an augmented T cell response, suggesting altogether that the activation of the PPARγ pathway may be of therapeutic relevance in MS. Furthermore, elevated expression of PPARγ has been reported within the spinal cord of EAE mice [8, 9] and in an in vitro model of antigen-induced demyelination [12] , supporting the notion that PPARγ may have a physiological role in the regulation of CNS inflammation in rodents. However, no reports have yet been available on the PPARγ status in the CNS of human individuals with MS. This study aimed to identify a possible alteration of PPARγ expression in MS, by assessing the levels of PPARγ protein in the CSF of MS patients.
Patients, materials and methods
The study included CSF samples of 35 
Results
In our study cohort, CSF levels of PPARγ were highly and significantly elevated in the CSF of patients with MS compared to Control (167.5 pg/ml [75. 6- 
Discussion
Our results demonstrate for the first time a pronounced elevation of PPARγ levels in the CSF of patients with MS, in association with increased CNS inflammatory parameters.
These results are in line with the prior reports on elevated expression of PPARγ in the CNS of EAE mice [8, 9] and may reflect a possible physiological compensatory role of PPARγ in the regulation of CNS autoimmunity in humans. This experimentally demonstrated regulatory function is supposed to be primarily attributable to the attenuation of inflammatory cytokine expression within microglia/macrophages and astrocytes [30, 33, 37] [24] , accompanied by a switch towards a Th2 response [10, 11] . In addition, activation of PPARγ expression in brain endothelial cells has been shown to be a negative regulator of lymphocytic transmigration [17] . Besides, PPARγ activation have also been demonstrated to have protective effects on neurons and oligodendrocytes [2, 10-12, 20, 26, 34, 36] . Furthermore, the activation of PPARγ has been associated with the promotion of oligodendrocyte differentiation and myelin production [3, 7, 15, 25, 31, 34] . These properties may all contribute to the positive effects of PPARγ activation in experimental CNS inflammation, and may be exploited in MS therapy. Based on the experimental findings, two small clinical studies have been performed with the synthetic agonist pioglitazone, the results of both supporting that the use of PPARγ agonists may be beneficial in MS [14, 32] .
Moreover, in a population-based study, the Pro12Ala polymorphism in the PPARG gene strongly associated with a delayed clinical onset of MS, which draws a further link between MS and PPARγ function [19] .
The source of the elevated levels of PPARγ observed in this study, however, is not entirely clear, and its determination will require further investigations. It is known that PPARγ is expressed in neurons, oligodendrocytes, astrocytes, microglia/macrophages [3] , T and B lymphocytes, dendritic cells [38] and brain endothelial cells [17] . In a murine EAE model of MS an increased expression of PPARγ has been reported in spinal cord homogenates [9] and in microglia/macrophages and astrocytes within the spinal cord lesions [8] . Furthermore, a strong upregulation of PPARγ has been observed in three-dimensional rat brain cultures following demyelination induced by antibodies directed against myelin oligodendrocyte glycoprotein [12] . Considering the neuropathological alterations in MS, the above listed experimental findings and our observation that PPARγ levels correlated with CSF inflammatory parameters, it is possible that PPARγ protein leaking out from injured/degenerating oligodendrocytes, neurons and astrocytes contribute to the observed elevation of its levels in the CSF. Considering that PPARγ upregulation has been demonstrated in activated macrophages [30] and activated T lymphocytes [4, 5] , and that PPARγ levels correlated with the CSF cell count in our study, the contribution of such cellular origin to the observed phenomenon may not be fully excluded either; however, the fact that our CSF samples were centrifuged almost immediately after LP suggest that the extent of a putative cell disintegration within the obtained sample should most probably be insufficient to cause such a significant alteration in the concentration of PPARγ in the supernatant. Though future investigations are necessary to conclude on the exact source of the observed elevation, the possible sources discussed -in light with the findings of prior experimental studiessuggest that the level of PPARγ in the CSF may reflect the severity of CNS involvement, which could account for the observed positive association with EDSS in our study.
The literature regarding alterations in PPARγ status in MS is rather sparse. Somewhat contradicting to our findings, another small clinical study examining peripheral white blood cells of MS patients reported decreased expression of PPARγ compared to control [18] . The findings of the two studies, however, are hard to compare, given that the studies focus on different compartments; furthermore, the patients enrolled in that study were either under immunomodulatory therapy or already in a secondary progressive phase, most probably representing different conditions compared to our untreated RR patients.
Conclusions
CSF levels of PPARγ were pronouncedly elevated in MS patients. This elevation was independent of blood-CSF barrier integrity, strongly correlated with white blood cell count, moderately correlated with IgG index, and displayed a moderate association with clinical severity. These results may contribute to our understanding about the role of PPARγ in the pathogenesis MS, and implicate this protein as a potential CSF biomarker of the disease.
Further research is necessary to determine the exact background of the observed alteration, and to assess the potential clinical relevance of this novel observation.
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